Skip to main content

Table 7 Effect of hypertonic saline and furosemide on urinary electrolytes and proteins in two spot urinary sample after examination in a randomized, cross-over study of 24 healthy subjects

From: Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects – a randomized controlled trial

  Spot 1 (day 1 post examination) Spot 2 (day 3–5 post examination)
U-Na (mmol/L)
 Placebo 79 (41;105) 50 (31;135)
 Furosemide 57 (27;98) 62 (32;151)*
U-K (mmol/L)
 Placebo 26 (15;37) 27 (14;44)
 Furosemide 34 (19;52) 30 (17;58)*
U-Cl (mmol/L)
 Placebo 78 (53;126) 63 (40;129)
 Furosemide 67 (38;116) 70 (45;186)
U-Creatinine (mmol/L)
 Placebo 4 (3;6) 5 (4;16)
 Furosemide 8 (4;13) 5 (3;13)*
U-Osmolality (mmol/L)
 Placebo 392 (200;467) 269 (195;710)*
 Furosemide 430 (236;663) 358 (214;740)*
U-Albumin (mg/L)
 Placebo 2 (1;5) 4 (2;7)
 Furosemide 5 (3;6) 4 (2;4)
U-ENaCγ (ng/ml)
 Placebo 0.29 (0.18;0.44) 0.35 (0.19;0.85)
 Furosemide 0.57 (0.27;0.92) 0.37 (0.21;0.92)
U-AQP2 (ng/ml)
 Placebo 0.40 (0.19;0.49) 0.37 (0.26;0.81)*
 Furosemide 0.68 (0.27;0.95) 0.36 (0.29;1.08)*
U-NGAL (ng/ml)
 Placebo 8.5 (3.8;23.8) 9.5 (2.8;22.3)*
 Furosemide 19.5 (4.0;40.5) 14.0 (3.0;25.5)*
U-KIM (ng/ml)
 Placebo 0.13 (0.08;0.17) 0.22 (0.09;0.35)*
 Furosemide 0.40 (0.09;0.57) 0.20 (0.08;0.49)*
  1. u-Na Urinary concentrations of sodium, u-K potassium, u-Cl chloride, creatinine, albumin, u-ENaCγ γ-fraction of the epithelial sodium channel, u-AQP2 aquaporin 2, u-NGAL neutrophil gelatinase-associated lipocalin and u-KIM-1 kidney injury, molecule-1. Data are shown as medians with 25 and 75 percentiles in brackets. Wilcoxon signed rank test was used to test statistically significant difference from spot 1, * = p < 0.05, and from Placebo,  = p < 0.05